ReviewFrontiers in immunology2021
HLA Desensitization in Solid Organ Transplantation: Anti-CD38 to Across the Immunological Barriers.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- Effect of felzartamab on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsies.Nature medicine · 2025Trial
- CD38 defines a therapeutically targetable pathogenic T cell population for precision immunotherapy in autoimmune diabetes.bioRxiv : the preprint server for biology · 2026Article
- Evolving Therapeutic Approaches for Treatment of Antibody-Mediated Rejection in Renal Allograft Recipients.Results and problems in cell differentiation · 2026Review
- Modeling the Application of Chimeric Antigen Receptor T Cell Therapy to Eliminate Alloantibodies in Mice.Methods in molecular biology (Clifton, N.J.) · 2026Article
- One tool, multiple gains: anti-CD38 therapy in antibody-mediated rejection.Clinical kidney journal · 2025Article
- Anti-CD38 Daratumumab Treatment of Chronic Active Antibody-Mediated Kidney Allograft Rejection.Kidney international reports · 2025Article
- Long-term outcomes of kidney transplantation in a transfusion-dependent alpha-thalassemia patient.CEN case reports · 2025Article
- Desensitization in HLA-incompatible kidney transplant recipients: current strategies and emerging perspectives.Clinical kidney journal · 2025Review
- Aberrant humoral immune responses and intestinal homeostasis in Cd38 Bst1 double knockout mice.ImmunoHorizons · 2025Article
- Review
- Advancements in noninvasive techniques for transplant rejection: from biomarker detection to molecular imaging.Journal of translational medicine · 2025Review
- Daratumumab for De-sensitization of Donor Specific Antibodies: Is it a Quicker and Easier way?Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2024Article
- Immunology demystified: A guide for transplant hepatologists.World journal of transplantation · 2024Review
- Translation of therapeutic strategies to modulate B cell reponses from non-human primate models to human kidney transplantation.Frontiers in transplantation · 2023Article
- A Novel Daratumumab-Based Regimen for Desensitization in Highly HLA-Presensitized Patients Awaiting Kidney Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2023Article
- Targeting CD38 in Neoplasms and Non-Cancer Diseases.Cancers · 2022Review
- Article
- Innovative immunosuppression in kidney transplantation: A challenge for unmet needs.World journal of transplantation · 2022Review
- Antibody-removal therapies for de novo DSA in pediatric intestinal recipients: Why, when, and how? A single-center experience.Frontiers in pediatrics · 2022Article
- Case report: Daratumumab for treatment of refractory late or chronic active antibody-mediated rejection in renal allograft recipients with high levels ofFrontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The presence of anti-human leucocyte antigen (HLA) antibodies in the potential solid organ transplant recipient's blood is one of the main barriers to access to a transplantation. The HLA sensitization is associated with longer waitlist time, antibody mediated rejection and transplant lost leading to increased recipient's morbidity and mortality. However, solid organ transplantation across the HLA immunological barriers have been reported in recipients who were highly sensitized to HLA using desensitization protocols. These desensitization regimens are focused on the reduction of circulating HLA antibodies. Despite those strategies improve rates of transplantation, it remains several limitations including persistent high rejection rate and worse long-term outcomes when compare with non-sensitized recipient population. Currently, interest is growing in the development of new desensitization approaches which, beyond targeting antibodies, would be based on the modulation of alloimmune pathways. Plasma cells appears as an interesting target given their critical role in antibody production. In the last decade, CD38-targeting immunotherapies, such as daratumumab, have been recognized as a key component in the treatment of myeloma by inducing an important plasma cell depletion. This review focuses on an emerging concept based on targeting CD38 to desensitize in the field of transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.